[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heavy-ion-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heavy-ion-radiotherapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100540062","phase-2-clinical-study-of-postoperative-carbon-ion-radiotherapy-for-thymus-tumor-with-residual-tumor-100540062",false,"NCT06311955","Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor","Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection","Inclusion Criteria:\n\n* Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis.\n* Sign informed consent.\n* Between the ages of 18 and 70.\n* ECOG general status score of 0-2.\n* The expected survival is at least 6 months.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109\u002FL, platelet count ≥80 x 109\u002FL, hemoglobin ≥9 g\u002FdL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\\u003C1.5 times the upper limit of normal value, and AST, ALT\\\u003C2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml \u002Fmin, and urinary protein \\\u003C2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n\nExclusion Criteria:\n\n* Complicated with other malignant tumors that have not been controlled.\n* Have large quantity of pleural or pericardial effusion.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.","ALL","18 Years","70 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.",[27,28,29,30],"Thymic Epithelial Tumor","Radiotherapy Side Effect","Carbon Ion Radiotheray","Heavy Ion Radiotherapy","RECRUITING","2025-06-10",{"date":34,"type":35},"2025-06-13","ACTUAL",{"date":37,"type":21},"2025-07-01",{"date":39,"type":21},"2029-02-28",{"name":41,"class":42},"Jian Chen","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100580013","clinical-study-of-carbon-ion-radiotherapy-for-high-grade-glioma-100580013","NCT06831773","Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma","Phase II Clinical Study of Carbon Ion Combined with Photon Radiotherapy for High-grade Glioma","Inclusion Criteria:\n\n1. Age ≥14 years and ≤80 years;\n2. Indications: According to the criteria of the 5th edition of WHO Classification of Central Nervous System Tumors published in 2021, histological characteristics and molecular phenotype were integrated, and the molecular phenotype was IDH wild-type glioma and IDH mutant WHO Grade Ⅲ and Ⅳ glioma. They mainly include: IDH wild-type low-grade glioma (Grade 4 astrocytoma according to the 2021 WHO classification definition); Anaplastic Astrocytoma, AA; anaplastic astrocytoma, AA; Anaplastic Oligodendroglioma, AOG; anaplastic oligodendroglioma, AOG; Anaplastic Oligoastrocytoma, AOA; anaplastic oligoastrocytoma, AOA; Glioblastoma Multiforme, GBM. Regardless of surgical completeness, i.e. after total, subtotal, or partial resection, and after stereotactic or craniotomy.\n3. No distant or intraspinal spread and metastasis; A single or two intracranial lesions may be covered by the same radiotherapy plan.\n4. The treatment conditions before this radiotherapy were as follows: First radiotherapy: no interventional, photodynamic or other tumor ablation was performed within 4 weeks before this radiotherapy; The operative wound has fully healed.\n5. Can accept MRI and enhanced CT examination, and there are no metal artifacts in CTV;\n6. No history of other malignant tumors (except cured skin cancer and stage 0 cervical cancer);\n7. Liver function, kidney function and bone marrow function were basically normal (ALT and AST \\\u003C 1.5 times of high normal value (ULN), bilirubin \\\u003C 1.5×ULN; Adult endogenous creatinine clearance rate of 60ml\u002Fmin or serum creatinine SCR≤140μmoI\u002FL, BUN≤6.8mmol\u002FL; Hemoglobin level \\>9 g\u002FdL; White blood cell count ≥3.0\\*109\u002FL; Platelet count ≥100\\*109\u002FL;)\n8. Good physical condition, i.e. ECOG (Eastern United States Oncology Collaboration Group) 0\\~2; There were no complications such as severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, and severe chronic heart disease that may affect radiotherapy. Cardiac function grade 1. (According to the New York College of Cardiology Cardiac Function Scale (NYHA)\n9. Adequate functions of major organs;\n10. Predicted survival (after treatment) ≥6 months;\n11. Informed consent has been signed by the patient or his legal representative before radiotherapy.\n\nExclusion Criteria:\n\n1. WHOII-IV glioma unconfirmed by pathology;\n2. Patients who cannot lie still for 30 minutes;\n3. Secondary treatment of recurrent tumors\n4. There have been distant metastases, or scattered or multiple (\\>2) intracranial lesions;\n5. Have received conventional photon\u002Fproton\u002Fcarbon ion radiotherapy to the head;\n6. Have received intracranial radioactive particle implantation with metal implants that may affect the dose of particle radiation therapy;\n7. Unable to receive MRI with claustrophobia or a pacemaker or metal implant\n8. Pacemakers or other metal implants that may be interfered with normal function by high-energy radiation or may affect the dose of radiation target;\n9. The dose limit for organs at risk cannot reach the preset safe dose limit\n10. Pregnancy (confirmed by serum or urine β-HCG test) or lactation\n11. losing more than 20% of your body weight within six months;\n12. Persons with AIDS, including those who have received antiretroviral therapy; Active stage of syphilis;\n13. Accompanied by serious comorbiditions, including uncontrolled systemic or co-existing diseases (pulmonary insufficiency, cardiovascular, pulmonary, liver, kidney, diabetes, etc.), drug or alcohol abuse, dependence, addiction, and\u002For mental illness that prevent the successful implementation of the trial protocol;\n14. Patients with poor compliance, including those who may not be able to complete the treatment plan or receive prescribed follow-up and examination;\n15. have had other malignant neoplasms (except cured skin cancer and stage 0 cervical cancer);\n16. There are contraindications to radiotherapy;\n17. Participated in other drug clinical trials within 30 days prior to enrollment in this study;\n18. having no or limited capacity for civil conduct;\n19. Any medical history that, in the investigator's judgment, might interfere with the trial results or increase the patient's risk;\n20. Any condition in which the physician considers that participation in the trial is not appropriate, the physician determines that the patient will not benefit from carbon ion radiotherapy, or that there are other co-existing conditions or other factors that may affect carbon ion therapy.\n21. Inability to understand the purpose of treatment or unwillingness\u002Finability to sign treatment consent.","14 Years","80 Years",{"count":54,"type":21},23,[56],"NA","The objective is to use the advantages of heavy ion physical dosimetry and biology to improve the tumor control rate and long-term survival rate of high-grade glioma, reduce the occurrence of brain tissue radiation damage caused by increasing prescription dose, and provide new treatment suggestions for glioma radiotherapy.",[29,59,30],"High-grade Glioma","2025-02-15",{"date":62,"type":35},"2025-02-18",{"date":64,"type":35},"2025-02-01",{"date":66,"type":21},"2027-12-31",{"name":68,"class":42},"Gansu Wuwei Tumor Hospital"]